Search

Displaying results 3301 - 3310 of 10000 in total
  1. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    [L49681] In September 2024, the drug was approved by Health Canada for the same indications. [L52850] … It was approved by the FDA in December 2023 for the treatment of patients with SCD with recurrent vaso-occlusive crises.

    Synonyms: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated
  2. Drug

    Xanthan gum

    go.drugbank.com/drugs/DB11253
    Approved

    Xanthan gum is a polysaccharide gum derived from* Xanthomonas campestris* by a pure-culture fermentation process and purified by recovery with isopropyl alcohol. … Xanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA. It is used as a thickening agent and stabilizer in emulsions.

  3. Drug

    Tenofovir

    go.drugbank.com/drugs/DB14126
    Investigational

    Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog....

  4. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).

  5. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

  6. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based). … GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides

  7. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli.

  8. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).

  9. Indication

    No primary neurological disease, idiopathic decreased mental activity

    go.drugbank.com/conditions/DBCOND0141360
    Drugs: Dihydro-alpha-ergocryptine · Dihydroergocornine · Dihydroergocristine · Epicriptine
    Synonyms: No primary neurological disease, idiopathic decreased mental activity, No primary neurologial disease, idiopathic decreased mental activity
  10. Drug

    Orphenadrine

    go.drugbank.com/drugs/DB01173
    ApprovedInvestigational

    A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.

    Synonyms: N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine, N,N-dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamine